ALDER BIOPHARMACEUTICALS INC 4
4 · ALDER BIOPHARMACEUTICALS INC · Filed Oct 5, 2016
Insider Transaction Report
Form 4
Schatzman Randall C
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2016-10-03$31.55/sh−2,700$85,189→ 114,768 total - Exercise/Conversion
Common Stock
2016-10-03$1.26/sh+8,181$10,349→ 122,949 total - Exercise/Conversion
Stock Option (Right to Buy)
2016-10-03−8,181→ 0 totalExercise: $1.26Exp: 2017-11-13→ Common Stock (8,181 underlying) - Sale
Common Stock
2016-10-03$30.95/sh−5,481$169,622→ 117,468 total
Footnotes (5)
- [F1]The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2015.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.35 to $31.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.36 to $32.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
- [F5]The shares subject to this stock option are fully vested.